Legal & General Group PLC Uni Qure N.V. Transaction History

Legal & General Group PLC

$440 Billion
Q2 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.71 - $11.83 $507,396 - $894,560	-75,618 Reduced 67.67%	36,132 $242,000
Q2 2023 Aug 14, 2023	SELL	$11.12 - $22.2 $14,989 - $29,925	-1,348 Reduced 1.19%	111,750 $1.28 Million
Q1 2023 May 15, 2023	SELL	$18.7 - $23.07 $22,645 - $27,937	-1,211 Reduced 1.06%	113,098 $2.28 Million
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $58,002 - $87,451	3,201 Added 2.88%	114,309 $2.59 Million
Q3 2022 Nov 14, 2022	BUY	$16.98 - $25.54 $212,861 - $320,169	12,536 Added 12.72%	111,108 $2.08 Million
Q2 2022 Aug 22, 2022	BUY	$13.15 - $20.45 $24,406 - $37,955	1,856 Added 1.92%	98,572 $1.84 Million
Q1 2022 May 16, 2022	SELL	$14.54 - $21.5 $11,050 - $16,340	-760 Reduced 0.78%	96,716 $1.75 Million
Q4 2021 Feb 14, 2022	BUY	$20.24 - $36.01 $64,059 - $113,971	3,165 Added 3.36%	97,476 $2.02 Million
Q3 2021 Nov 15, 2021	BUY	$26.01 - $38.22 $1.99 Million - $2.92 Million	76,489 Added 429.18%	94,311 $3.02 Million
Q4 2020 Feb 12, 2021	BUY	$35.35 - $50.67 $169,079 - $242,354	4,783 Added 36.68%	17,822 $644,000
Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $6,308 - $9,483	140 Added 1.09%	13,039 $588,000
Q1 2020 May 14, 2020	BUY	$40.01 - $73.97 $110,747 - $204,748	2,768 Added 27.32%	12,899 $612,000
Q4 2019 Feb 13, 2020	BUY	$37.13 - $74.62 $10,470 - $21,042	282 Added 2.86%	10,131 $726,000
Q3 2019 Nov 13, 2019	BUY	$39.36 - $76.8 $349,674 - $682,291	8,884 Added 920.62%	9,849 $388,000
Q4 2018 Feb 15, 2019	BUY	$22.8 - $33.93 $15,960 - $23,751	700 Added 264.15%	965 $28,000
Q2 2018 Aug 10, 2018	BUY	$21.96 - $39.94 $5,819 - $10,584	265 New	265 $10,000

Others Institutions Holding QURE

# of Institutions

142

Shares Held

35.3M

Call Options Held

1.54M

Put Options Held

389K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account